Funder
National Natural Science Foundation of China
Clinical Medicine Science and Technology Special Project of the Jiangsu Province, China
Publisher
Springer Science and Business Media LLC
Reference60 articles.
1. Gansler T, Ganz PA, Grant M, Greene FL, Johnstone P, Mahoney M, Newman LA, Oh WK, Thomas CR Jr, Thun MJ, Vickers AJ, Wender RC, Brawley OW (2010) Sixty years of CA: a cancer journal for clinicians. CA Cancer J Clin 60(6):345–350. https://doi.org/10.3322/caac.20088
2. Austreid E, Lonning PE, Eikesdal HP (2014) The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy. Expert Opin Pharmacother 15(5):681–700. https://doi.org/10.1517/14656566.2014.885952
3. Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C, Barnes D, Peters G (1994) Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 54(7):1812–1817
4. Ali S, Coombes RC (2002) Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2(2):101–112. https://doi.org/10.1038/nrc721
5. Alves CL, Elias D, Lyng MB, Bak M, Kirkegaard T, Lykkesfeldt AE, Ditzel HJ (2016) High CDK6 protects cells from fulvestrant-mediated apoptosis and is a predictor of resistance to fulvestrant in estrogen receptor-positive metastatic breast cancer. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-15-1984
Cited by
28 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献